NCT05202145View on ClinicalTrials.gov

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

March 21, 2022

Study Completion Date

March 21, 2022

Conditions
Healthy
Interventions
DRUG

ALXN2050

Oral tablet.

DRUG

Cyclosporine

Oral capsule.

DRUG

Tacrolimus

Oral capsule.

DRUG

MMF

Oral tablet.

Trial Locations (1)

85283

Clinical Study Site, Tempe

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY